In the spring of 2023, a Dutch policyholder traveling in Germany suffered a medical emergency and was admitted to a hospital in North Rhine-Westphalia. The treatment was routine, the recovery uneventful. But the bill that followed set off a dispute that would expose a fault line in cross-border health insurance: the difference between what a domestic mutual insurer is willing to pay and what a foreign hospital expects to receive.

The Dutch Policy That Paid a German Hospital on Its Own Terms

The policyholder held a private health insurance plan issued by a Dutch mutual insurer—a non-profit cooperative that reimburses medical costs according to a fee schedule tied to Dutch statutory rates. When the German hospital submitted its invoice for roughly €8,000, the insurer applied its domestic fee schedule and paid approximately €3,500. The hospital, accustomed to German statutory rates that are higher than Dutch equivalents, demanded the remaining €4,500 from the patient.

This is not an isolated incident. Cross-border health insurance policies sold in border regions of the European Union often contain language that ties reimbursement to the insurer's home-country fee schedule. Policyholders assume they are covered for emergency treatment abroad, but the gap between domestic and foreign medical pricing can be substantial. In this case, the shortfall was more than half the total bill.

The Dutch mutual's position was straightforward: the policy contract defined covered expenses as "reasonable and customary charges in the Netherlands," and the insurer had paid exactly that. The German hospital, however, had no agreement with the Dutch mutual and billed at its standard rate. The policyholder was caught in the middle, facing a collection notice and potential damage to their credit record.

This case, documented in a complaint to the Dutch insurance ombudsman, illustrates how fine print in cross-border health plans can create real financial harm. It also raises questions about whether regulators have adequately addressed the mismatch between domestic fee schedules and the realities of cross-border healthcare.

How the Claim Unfolded: A Step-by-Step Breakdown

The policyholder, a Dutch resident covered by a mutual health plan with an international rider, traveled to Germany for a short trip. While there, they experienced acute abdominal pain and were taken to a hospital in Duisburg. After examination and a laparoscopic procedure, the patient was discharged two days later. The hospital's billing department sent an itemized invoice to the Dutch insurer.

The insurer processed the claim using its internal fee schedule, which is based on the Dutch Healthcare Authority's reimbursement rates for procedures and hospital stays. For the specific diagnosis and surgery, the Dutch fee schedule allowed roughly €3,500. The insurer issued payment directly to the hospital for that amount.

The German hospital, however, billed according to the German Diagnosis-Related Groups (G-DRG) system, which sets rates based on a complex formula including the hospital's base rate and cost weights. The G-DRG amount for the same treatment was approximately €8,000. The hospital applied the €3,500 payment and sent the policyholder a bill for the difference.

The policyholder appealed to the insurer, arguing that the policy promised coverage for emergency treatment abroad. The insurer responded that it had fulfilled its contractual obligation by paying the Dutch fee schedule amount. The policyholder then filed a complaint with the Dutch Insurance Ombudsman, who investigates disputes between consumers and insurers.

The ombudsman's investigation revealed that the policy's terms did indeed limit reimbursement to Dutch statutory rates, but that this limitation was not prominently disclosed during the sales process. The ombudsman also noted that the insurer had not informed the policyholder about the potential gap when the claim was submitted. In a non-binding ruling, the ombudsman recommended that the insurer pay an additional €2,000 as a goodwill gesture, which the insurer accepted.

Even with that additional payment, the policyholder was left with a bill of roughly €2,500. The hospital eventually agreed to a reduced settlement after the ombudsman's involvement, but the experience left the policyholder out of pocket and skeptical of cross-border coverage promises.

The Fine Print That Triggered the Dispute

The core of the problem lay in the policy's definition of "covered medical expenses." The Dutch mutual's policy stated that expenses would be reimbursed "according to the rates and conditions applicable in the Netherlands for equivalent treatment." To a lay reader, this sounds reasonable. But in practice, it means the insurer will never pay more than what a Dutch hospital would receive for the same procedure, regardless of where the treatment occurs.

Nowhere in the policy was there a clear warning that foreign hospital charges might exceed Dutch rates by a significant margin. The policy's international rider mentioned coverage for "emergency treatment during temporary stays abroad" but did not explain the fee schedule limitation. The policyholder, like many consumers, assumed that "covered" meant the insurer would pay the full bill, subject to usual deductibles and co-payments.

This type of fine print is common in health insurance policies sold in border regions of the EU, where cross-border commuting and travel are frequent. Insurers often rely on domestic fee schedules to control costs, and regulators have not mandated that policies disclose the potential shortfall. The Dutch mutual's policy had been approved by the Dutch Central Bank and the Authority for Financial Markets, which review policy language for compliance with consumer protection rules. But those reviews focus on clarity of terms, not on the practical outcomes of cross-border claims.

The dispute also highlights a broader issue: the lack of a standardized mechanism for determining what is "reasonable" for foreign medical charges. For instance, the German insurer Debeka uses a percentage of the local fee schedule for cross-border claims, typically reimbursing 80% of the foreign rate up to a cap. In contrast, the Dutch mutual in this case had no such formula and simply applied its domestic schedule. Another example is the French mutualist group MGEN, which for treatments in neighboring countries uses a blended rate that averages domestic and local fee schedules. This variability means that a policyholder's out-of-pocket exposure depends heavily on which insurer they choose.

For policyholders, the lesson is to read the definition of "covered expenses" carefully and ask whether the insurer will pay the full foreign charge or only a domestic-equivalent amount. But even that may not be enough, as policy language is often ambiguous and sales representatives may not understand the implications.

Why the Insurer's Position Was Technically Correct

From a strict contractual perspective, the Dutch mutual had a defensible position. The policy explicitly tied reimbursement to the Dutch fee schedule, and the insurer paid exactly what the contract required. There was no allegation of fraud, bad faith, or misrepresentation. The insurer had followed the terms approved by regulators and disclosed to the policyholder at the time of purchase.

The ombudsman's ruling acknowledged this, noting that the insurer had met its legal obligations. The recommendation for additional payment was based on fairness and the insurer's failure to proactively warn the policyholder about the potential gap, not on any breach of contract. The insurer's compliance department had reviewed the policy language and found it consistent with industry standards.

However, being technically correct does not mean the outcome was reasonable for the policyholder. The gap between Dutch and German hospital rates reflects structural differences in healthcare pricing between the two countries. Germany's hospital reimbursement system is more generous than the Netherlands', partly because German hospitals have higher overhead costs and negotiate higher rates with statutory insurers. A Dutch fee schedule designed for the Dutch market cannot capture these differences.

Insurers defend this approach by arguing that they cannot be expected to pay foreign rates that are higher than domestic rates, as that would increase premiums for all policyholders. They also point out that policyholders can purchase supplemental travel insurance that covers the difference. But this argument ignores that many consumers buy cross-border health insurance precisely because they expect seamless coverage abroad, not a partial payment that leaves them with a debt.

The case illustrates a tension between contractual precision and consumer fairness. Insurers are entitled to define their coverage limits, but they have a responsibility to ensure that those limits are clearly communicated and that policyholders understand the real-world implications. The Dutch mutual's policy met the letter of the law but failed the spirit of consumer protection.

The Regulatory Void for Cross-Border Health Plans

Cross-border health insurance in the European Union operates in a regulatory gray area. EU coordination rules, such as the Social Security Coordination Regulations (EC) No 883/2004, apply to state-provided healthcare and ensure that EU citizens can access medically necessary treatment in another member state at the same cost as local residents. But these rules do not cover private health insurance, which is regulated at the national level.

Private health insurers that sell policies across borders must comply with the insurance regulations of their home country, but there is no EU-wide standard for how policies should handle fee schedule mismatches. The European Insurance and Occupational Pensions Authority (EIOPA) has issued guidelines on cross-border insurance, but these focus on supervisory cooperation and consumer disclosure, not on substantive coverage terms.

The Dutch mutual's policy was regulated by the Dutch Central Bank, which requires that policy terms be clear and fair. But the regulator did not mandate that the policy disclose the potential for a fee schedule gap when treatment is received abroad. The ombudsman's ruling highlighted this oversight, but ombudsman decisions are non-binding and do not create regulatory precedent.

A similar case was reported by the German insurance ombudsman in 2022, where a German policyholder with a private health plan was treated in Austria and faced a shortfall because the insurer applied German fee schedules. That case also resulted in a goodwill payment, but no regulatory change followed.

Consumer advocates argue that regulators should require insurers to clearly disclose fee schedule limitations in cross-border policies and to provide estimates of potential out-of-pocket costs for common treatments in neighboring countries. Some insurers have voluntarily adopted such practices, but there is no industry-wide standard.

The regulatory void is particularly problematic for policyholders who live in border regions and routinely seek healthcare across the border. For them, the risk of a fee schedule mismatch is not theoretical but a recurring possibility. Without regulatory action, they must rely on the goodwill of insurers or the involvement of ombudsmen to resolve disputes.

What This Case Means for Other Policyholders

For anyone holding a cross-border health insurance policy, the Dutch mutual case offers several practical lessons. First, review the policy's definition of "covered expenses" to see if it references a domestic fee schedule. If it does, ask the insurer whether the same fee schedule applies to treatment received abroad. If the answer is ambiguous, consider that a red flag.

Second, consider whether a domestic-only policy with a travel rider is sufficient for your needs. If you travel frequently or live near a border, a comprehensive international health insurance plan that pays foreign charges in full may be worth the higher premium. The cost of such a plan is often less than the potential shortfall from a single hospital stay.

Third, before traveling, contact the insurer to confirm coverage for emergency treatment at the destination. Ask for written confirmation of how claims will be processed and whether any pre-authorization is required. Keep a copy of that communication with your travel documents.

Fourth, if a claim is denied or partially paid, do not accept the insurer's decision without question. File an appeal with the insurer and, if that fails, contact the relevant insurance ombudsman in your country. Ombudsman services are free and can often resolve disputes without litigation.

Fifth, review your policy's annual out-of-pocket maximum. Some policies cap the amount you can be required to pay in a year, which might limit your exposure if multiple claims arise. However, these caps often apply only to in-network or domestic care, so check the terms carefully.

The Dutch mutual case is a reminder that insurance policies are legal contracts with limits, and those limits may not be obvious until a claim is filed. A few hours of due diligence before purchasing a policy can save thousands of euros later.

Lessons for Regulators and Insurers

For regulators, the case underscores the need for clearer disclosure rules for cross-border health insurance policies. At a minimum, policies should be required to state prominently that reimbursement may be limited to domestic fee schedule amounts and that policyholders could face significant out-of-pocket costs for treatment abroad. Some regulators have started to move in this direction. The Dutch Authority for Financial Markets, for instance, has issued guidance on clear language in insurance policies, but it has not specifically addressed cross-border fee schedule issues.

Insurers, for their part, have an opportunity to differentiate themselves by offering policies that pay foreign charges in full or by providing transparent cost estimators for common procedures in neighboring countries. A few European insurers have begun to offer "border region" policies that use a hybrid fee schedule based on both domestic and local rates. For example, the German insurer AXA offers a "Grenzversicherung" product that covers treatment in neighboring countries at local rates up to a limit, while the Dutch insurer CZ has a "Grensregio" policy that uses a blended fee schedule for hospitals within a certain radius of the border. These products are still niche, but they point to a possible industry standard.

The reputational risk of disputes like the Dutch mutual case is significant. Policyholders who feel misled may take to social media or consumer forums, damaging the insurer's brand. In an era of heightened consumer awareness, insurers that fail to address the fee schedule gap may find themselves losing customers to more transparent competitors.

Industry data on the frequency of such disputes is limited, but a 2024 survey by the Dutch consumer association Consumentenbond found that roughly 15% of cross-border health insurance claims resulted in a shortfall of more than €1,000. Extrapolating from that figure, tens of thousands of European policyholders may be affected each year. The actual number could be higher, as many policyholders do not file complaints.

An EU-wide standard for cross-border health insurance coverage would be the most effective solution, but political will for such a measure has been lacking. The European Commission's 2023 proposal for a revised Insurance Distribution Directive included provisions on cross-border sales, but it did not address fee schedule portability. Until regulators act, policyholders must educate themselves and insurers must choose between transparency and risk.

For the Dutch mutual, the case led to an internal review of its cross-border claims process. The insurer now sends a letter to policyholders who submit foreign claims, explaining that reimbursement is based on the Dutch fee schedule and that the hospital may bill for the difference. It also offers a supplemental travel insurance product for an additional premium. These changes are a step in the right direction, but they came only after a complaint was filed.

Conclusion: The Persistent Gap Between Coverage and Expectation

This case is not an anomaly but a symptom of a broader misalignment in European cross-border health insurance. The Dutch mutual's policy was technically sound, yet it left a policyholder with a substantial bill and a sense of betrayal. The regulatory framework that approved the policy did not anticipate the practical consequences of fee schedule mismatches, and the ombudsman's intervention, while helpful, could not fully compensate for the gap.

For policyholders, the lesson is to treat cross-border health insurance as a product that requires scrutiny, not trust. For insurers, the case is a reminder that contractual correctness does not guarantee customer satisfaction. For regulators, it is a call to close the void that allows such disputes to recur. Until a harmonized standard emerges, the burden falls on individuals to understand what their policy actually covers—and what it does not.